Biogen has announced a deal to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion with the potential for an additional $650 million based on milestones. HI-Bio focuses on a targeted approach to treating autoimmune diseases by depleting immune cells causing disorders. Their lead program, felzartamab, is in mid-stage clinical development for three indications. Biogen aims to diversify beyond multiple sclerosis drugs, with recent strategic additions in immunology. This acquisition strengthens Biogen’s presence in immunology and expands their pipeline. The deal is expected to close in the third quarter, with HI-Bio’s employees joining Biogen’s team in the San Francisco Bay Area.
Source link
Biogen Immunology Strategy Comes Into Focus With $1B HI-Bio Acquisition
